natgillin/translations-raw huggingface dataset:
Influenza-lignende symptomer herunder gigt (artitis) og hævede led.
Flu-like symptoms including arthritis and joint swelling.
Influenza-lignende symptomer herunder gigt (artritis) og hævede led.
Flu-like symptoms including arthritis and joint swelling
Influenza-lignende symptomer herunder gigt (artritis) og hævede led.
Flu-like symptoms including arthritis and joint swelling.
Influenza-lignende symptomer*, kulderystelser *
Influenza like illness*, chills
influenza-lignende symptomer, kuldegysninger, ændret temperaturopfattelse, nattesved, rødmen
flu-like symptoms, chills, altered temperature perception, night sweats, flushing
Influenza-lignende symptomer:
Flu-like symptoms:
Influenza-vaccine (H1N1)v (split virion, inaktiveret, adjuveret)
Influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)
Influenza.
Flu.
influenza; lokaliseret infektion; betændelse i næse og hals (nasofaryngit),
influenza; localised infection; inflammation of the passages in the nose and throat (nasopharyngitis);
Influenzalign. symptomer &  *°
Flu-like symptoms &  *°
Influenzalignen- de sygdom*
Influenza like illness
Influenzalignen- de sygdom* træthed
illness*, Fatigue
Influenzalignen- de sygdom* træthed
Influenza like illness*, Fatigue
Influenzalignend e symptomer Smerte
Flu-like syndrome Pain Asthenia
Influenzalignende
Depression
Influenzalignende
Dyspnoea
Influenzalignende
Influenza-like
influenzalignende sygdom
flu-like illness
influenzalignende sygdom
influenza like illness
influenzalignende sygdom
influenza-like illness
influenzalignende sygdom hvileløshed
influenza like illness restlessness
Influenzalignende sygdom*
Influenza-like illness
influenzalignende sygdom,
influenza like illness
Influenzalignende sygdom, afskalning ved injektionsstedet, misfarvning ved injektionsstedet, pruritus ved injektionsstedet, uspecificeret udslæt ved injektionsstedet, reaktion ved injektionsstedet, ardannelse ved injektionsstedet, hypertermi, smerte/ømhed
Influenza-like illness, Injection-site desquamation, Injection-site discoloration, Injection-site pruritus, Injection-site rash non-specific, Injection-site reaction, Injection-site scar, Hyperthermia, Pain, Pain/Tenderness/Soreness
Influenzalignende sygdom, asteni
Influenza like illness, asthenia
Influenzalignende sygdom, hævede arme, vægtstigning, træthed
Influenza-like illness, swelling arms, weight increase, fatigue
influenzalignende sygdom, pyreksi, kulderystelser, varmefølelse
influenza like illness, pyrexia, chills, feeling hot
Influenzalignende symptomer
Flu like symptoms.
influenzalignende symptomer
Flu-like illness
Influenzalignende symptomer
Flu-like symptoms (influenza)
influenzalignende symptomer
influenza-like symptoms,
Influenzalignende symptomer (cancerpatienter)
"Flu-like" symptoms (cancer patients)
Influenzalignende symptomer (patienter med kronisk nyreinsufficiens)
"Flu-like" symptoms (chronic renal failure patients)
influenzalignende symptomer hævede arme
flu-like symptoms swelling arms
Influenzalignende symptomer i forbindelse med injektion af interferon beta 1a kan virke stressende på patienter med hjertesygdomme.
Symptoms of the flu-like syndrome associated with interferon beta-1a therapy may prove stressful to patients with cardiac conditions.
influenzalignende symptomer som hovedpine, utilpashed, træthed, muskelsmerter smerter på injektionsstedet, rødme.
flu-like symptoms such as headache, feeling of discomfort, tiredness, muscle pain. injection site pain, reddening.
Influenzalignende symptomer som høj feber, ondt i halsen, løbende næse, hoste og kulderystelser.
Flu-like symptoms such as high temperature, sore throat, runny nose, cough and chills
Influenzalignende symptomer såsom feber, kuldegysninger, svækkelse, træthed
Flu-like symptoms, such as fever, chills, feeling of weakness, tiredness;
influenzalignende symptomer – kulderystelser og svedeture
a flu-like feeling — chills and sweating
influenzalignende symptomer – kulderystelser og øget svedtendens
a flu-like feeling – chills and sweating
influenzalignende symptomer,
flu like symptoms (influenza like illness);
influenzalignende symptomer, +feber, infusionsrelateret reaktion, reaktion på injektionsstedet, smerter på infusionsstedet, smerter på injektionsstedet
Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness, +Fever, Infusion related reaction, Injection site reaction, Infusion site pain, Injection site pain
influenzalignende symptomer, en generel følelse af utilpashed eller smerter
flu-like symptoms, feeling generally unwell or in pain
influenzalignende symptomer, følelse af utilpashed eller smerte
flu-like symptoms, feeling generally unwell or in pain
Influenzalignende symptomer, herunder høj feber, ondt i halsen, løbende næse, hoste og kuldegysninger
Flu-like symptoms such as high temperature, sore throat, runny nose, cough and chills
Influenzalignende symptomer, hovedpine, ledsmerter, svaghedsfølelse, træthed og svimmelhed.
Flu-like symptoms, headache, joint pain, feeling of weakness, tiredness and dizziness.
Influenzalignende symptomer, irritation og betændelse i mave-tarm-kanalen, bBetændelse i mave-tarm-kanalen, der forårsager diarré i forbindelse med antibiotika, betændelse i lymfekar
Flu-like symptoms, irritation and inflammation of the gastrointestinal tract, inflammation of the gastrointestinal tract causing antibiotic associated diarrhoea, inflammation of the lymphatic vessels
Influenzalignende symptomer, irritation og betændelse i mave-tarm-kanalen, betændelse i mave-tarm-kanalen, der forårsager diarré i forbindelse med antibiotika, betændelse i lymfekar
Flu-like symptoms, irritation and inflammation of the gasteointestinal tract, inflammation of the gastrointestinal tract causing antibiotic associated diarrhoea, inflammation of the lymphatic vessels
Influenzalignende symptomer, irritation og betændelse i mave-tarm-kanalen, betændelse i mave-tarm-kanalen, der forårsager diarré i forbindelse med antibiotika, betændelse i lymfekar
Flu-like symptoms, irritation and inflammation of the gastrointestinal tract, inflammation of the gastrointestinal tract causing antibiotic associated diarrhoea, inflammation of the lymphatic vessels
Influenzalignende symptomer, kulderystelser, træthed, asteni, smerter, utilpashed, reaktioner på infusionsstedet
Flu-like symptoms, chills, fatigue, asthenia, pain, malaise, infusion site reaction
influenzalignende symptomer, muskelsvaghed
flu-like symptoms, muscle weakness
influenzalignende symptomer, nervøsitet, fremmedfølelse, multiorgansvigt, trykken for brystet, temperaturintolerans
influenza like illness, feeling jittery, feeling abnormal, multi-organ failure, chest pressure sensation, temperature intolerance
influenzalignende symptomer, nervøsitet, fremmedfølelse, multiorgansvigt, trykken for brystet, temperaturintolerans
weight decreased, influenza like illness, feeling jittery, feeling abnormal, multi-organ failure, chest pressure sensation, temperature intolerance
influenzalignende symptomer, peri- fere ødemer/væske- retention
Flu-like symptoms, peripheral oedema/ fluid retention
influenzalignende symptomer, perifere ødemer/væskere- tention
Flu-like symptoms, peripheral oedema/ fluid retention
influenzalignende symptomer, røde pletter under huden
flu-like symptoms, red spots under the skin
Influenzalignende symptomer, symptomer fra luftvejene, kulderystelser, generelle smerter, svaghed
Flu -like symptoms, chestiness, chills, general pain, weakness
Influenzalignende symptomer, såsom hovedpine, feber, kulderystelser, smerter i muskler og led, træthed og kvalme er meget almindelige (kan forekomme hos flere end 1 ud af 10 personer).
Flu-like symptoms, such as headache, fever, chills, muscle and joint pains, fatigue and nausea are very common (may affect more than 1 in 10 people).
Influenzalignende symptomer, såsom hovedpine, ømhed og smerter i leddene, følelse af svaghed, kulderystelser, træthed og svimmelhed.
Flu-like symptoms, such as headache, aches and pains in the joints, feeling of weakness, chills, tiredness and dizziness.
Influenzalignende symptomer, udmattethed.
Flu-like illness, fatigue.
Influenzalignende symptomer.
Flu-like symptoms.
Influenzalignende symptomer.
Influenza-like syndrome.
Influenzalignende symptomer: ikke rigtig influenza
Flu-like symptoms: not really flu
Influenzaprofylakse hos personer i alderen 24 måneder op til 18 år.
Prophylaxis of influenza in individuals 24 months to less than 18 years of age.
influenzasymptomer
flu symptoms
Influenzasymptomer
Flu syndrome
Influenzasymptomer.
Flu syndrome.
Influenzavaccine (H1N1)v (hel virus, vero-celleafledt, inaktiveret) i.m.
Influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated) Intramuscular use
Influenzavaccine (H1N1)v (hele virion, vero-celleafledt, inaktiveret)
Influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated)
Influenzavaccine (hel virion, inaktiveret) der indeholder antigen*:
Influenza vaccine (whole virion, inactivated) containing antigen
Influenzavaccine (hel virion, inaktiveret) der indeholder antigen*:
Influenza vaccine (whole virion, inactivated) containing antigen of*:
Influenzavaccine (levende svækket, nasal)
Influenza vaccine (live attenuated, nasal)
Influenzavaccine (overfladeantigen, inaktiveret, tilberedt i cellekulturer)
Influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
Influenzavaccine H1N1v (overfladeantigen, inaktiveret, adjuveret)
Influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)
Influenzavaccine Sæson 2013/2014
Influenza vaccine 2013/2014 season
Influenzavaccine, ATC-kode: J07BB02 Klinisk virkning og sikkerhed
Influenza vaccine, ATC Code: J07BB02 Clinical efficacy and safety
Influenzavaccine, hel virion H5N1, inaktiveret indeholdende antigen*:
Whole virion H5N1 influenza vaccine, inactivated, containing antigen of*:
Influenzavaccine, hel virus, inaktiveret, indeholder antigen af stamme*:
Whole virus influenza vaccine, inactivated containing antigen of strain*:
Influenzavaccine, hele virion, inaktiveret, indeholder antigen af stamme*:
Whole virion influenza vaccine, inactivated, containing antigen of strain*:
Influenzavaccine, hele virion, inaktiveret, indeholder antigen fra stamme*:
Whole virion influenza vaccine, inactivated containing antigen of strain *:
Influenzavaccine,(hel virion, inaktiveret) indeholdende antigen*: A/Vietnam/1203/2004 (H5N1) 7,5 mikrogram** pr.
Influenza vaccine (whole virion, inactivated) containing antigen * of: A/Vietnam/1203/2004 (H5N1) 7.5 micrograms**per
Influenzavaccine,(hel virion, inaktiveret) indeholdende antigen*: A/Vietnam/1203/2004 (H5N1) 7,5 mikrogram** pr.
Influenza vaccine (whole virion, inactivated) containing antigen* of: A/Vietnam/1203/2004 (H5N1) 7.5 micrograms**per
Influenzavirus overfladeantigen (hæmagglutinin og neuraminidase)* af følgende stamme:
Influenza virus surface antigens (haemagglutinin and neuraminidase)* of strain:
Influenzavirus-overfladeantigener (hæmagglutinin og neuraminidase)* af stammen: A/California/07/2009 (H1N1)-deriveret stamme fra NYMC X-181) 7,5 mikrogram** per 0,5 ml dosis
A/California/07/2009 (H1N1)-derived strain used NYMC X-181 7.5 micrograms** per 0.5 ml dose
Influenzavirus-overfladeantigener (hæmagglutinin og neuraminidase)*, inaktiverede, fra følgende stammer:
Influenza virus surface antigens (haemagglutinin and neuraminidase)*, inactivated, of the following strains:
Influenzavirusstammerne i Pandemisk influenzavaccine H5N1 MedImmune er (a) koldtadapterede (cold-adapted, ca); (b) temperaturfølsomme (temperature-sensitive, ts) og (c) svækkede (attenuated, att).
The influenza virus strain in Pandemic influenza vaccine H5N1 MedImmune is (a) cold-adapted (ca); (b) temperature-sensitive (ts); and (c) attenuated (att).
influenza–lignende sygdom vægttab
flu-like illness weight loss
INFORMACIÓN EN BRAILLE
INFORMATION IN BRAILLE
INFORMACIÓN MÍNIMA QUE DEBE INCLUIRSE EN PEQUEÑOS ACONDICIONAMIENTOS PRIMARIOS
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
INFORMACIÓN QUE DEBE FIGURAR EN EL ACONDICIONAMIENTO PRIMARIO
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE
INFORMACIÓN QUE DEBE FIGURAR EN EL EMBALAJE EXTERIOR CAJA DE CARTÓN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON
Información para que el paciente sepa cuándo debe solicitar atención médica urgente
When to seek urgent attention from the health care provider
Información sobre crisis o infecciones
Information on crisis or infections
Información sobre seguimiento por parte de los padres del desarrollo de los niños tratados
Information on growth follow-up of treated children for their parents
INFORMATIE IN BRAILLE
INFORMATION IN BRAILLE
Information fra kliniske forsøg
Information on Clinical Trials
Information fra kliniske studier
Clinical trial information
Information hvoraf det fremgår, at du har diabetes.
Information so that others know you have diabetes.
INFORMATION I BRAILLE-SKRIFT
INFORMATION IN BRAIILE
INFORMATION I BRAILLE-SKRIFT
INFORMATION IN BRAILLE (CARTON ONLY)
INFORMATION I BRAILLE-SKRIFT
INSTRUCTIONS ON USE
INFORMATION I BRAILLE-SKRIFT
NAME OF THE MEDICINAL PRODUCT
INFORMATION I BRAILLE_SKRIFT
INFORMATION IN BRAILLE
INFORMATION I BRAILLES-KRIFT
INFORMATION IN BRAILLE
INFORMATION I BRAILLESKRIFT
16.INFORMATION IN BRAILLE
INFORMATION I BRAILLESKRIFT
INFO RMATIO N IN BRAILLE
INFORMATION I BRAILLESKRIFT
Read the package leaflet before use.
INFORMATION I BRAILLESKRIFT (kun på den ydre pakke)
INFORMATION IN BRAILLE
INFORMATION I BRAILLESRIFT
INFORMATION IN BRAILLE
Information médicale: tél: +33(0) 800 100 499
Information médicale: tél:+33(0) 800 100 499
Information om administration af en 0,5 ml dosis IXIARO til personer på 3 år og derover
Information on the administration of a 0.5 ml dose of IXIARO for persons 3 years of age and above
Information om amyloid patologi ved Alzheimers sygdom
Information on amyloid pathology in Alzheimer’s disease;
Information om amyloid-patologi ved Alzherimers sygdom; relevant information om Amyvids egenskaber som et β-amyloid PET-sporstof, herunder den godkendte indikation i henhold til produktresumeet, begrænsninger i anvendelsen af Amyvid, tolkningsfejl, sikkerhedsinformation samt resultaterne af kliniske studier med information om den diagnostiske anvendelse af Amyvid.
Information on amyloid pathology in Alzheimer Disease; relevant information on Amyvid as an β-amyloid PET tracer, including the approved indication according to the SmPC, limitations of Amyvid use, interpretation errors, safety information and the results of clinical trials informing on the diagnostic use of Amyvid
Information om amyloid-patologi ved Alzherimers sygdom; relevant information om Vizamyls egenskaber som et β-amyloid PET-sporstof, herunder den godkendte indikation i henhold til produktresumeet, begrænsninger i anvendelsen af Vizamyl, tolkningsfejl, sikkerhedsinformation samt resultaterne af kliniske studier med information om den diagnostiske anvendelse af Vizamyl.
Information on amyloid pathology in Alzheimer Disease; relevant information on VIZAMYL as an β-amyloid PET tracer, including the approved indication according to the SmPC, limitations of VIZAMYL use, interpretation errors, safety information and the results of clinical trials informing on the diagnostic use of VIZAMYL.
Information om antibiotisk følsomhedsbestemmelse
Laboratory susceptibility testing leaflet
Information om anvendelse af IMLYGIC i forbindelse med graviditet
Information on IMLYGIC use in pregnancy
Information om anvendelse af IMLYGIC i forbindelse med graviditet;
Information on IMLYGIC use in pregnancy;
Information om at søge akut lægehjælp i tilfælde af bivirkninger under en infusion.
Instruction to seek emergency treatment by healthcare professionals in the event of any adverse reactions during an infusion
Information om behandling af hyperglykæmi findes i den indrammede del sidst i indlægssedlen.
For information on the treatment of hypoglycaemia, see box at the end of this leaflet.
Information om behandling af hyperglykæmi findes i det indrammede afsnit sidst i indlægssedlen.
For information on the treatment of hyperglycaemia, see the box at the end of this leaflet.
Information om behandling af hyperglykæmi findes i det indrammede afsnit sidst i indlægssedlen.
For information on the treatment of hypoglycaemia, see box at the end of this leaflet.
Information om behandling af hypoglykæmi findes i den indrammede del sidst i indlægssedlen.
For information on the treatment of hyperglycaemia, see box at the end of this leaflet.
Information om behandling af hypoglykæmi findes i det indrammede afsnit sidst i indlægssedlen.
For information on the treatment of hyperglycaemia, see box at the end of this leaflet.
Information om behandling med BLINCYTO, administration og dosering, varighed af hospitalsindlæggelse, afbrydelse og/eller permanent seponering af behandlingen
Information on treatment with BLINCYTO, administration and posology, duration of hospitalisation, interruption and / or permanent discontinuation of the treatment
Information om behovet for at føre dagbog, for at dokumentere hver indgivet behandling i hjemmet, og om at bringe dagbogen til hvert besøg.
Information on the need to keep a diary to document each treatment received at home and to bring it at each visit.
Information om behovet for, at lægemidlet håndteres under sterile betingelser
need to handling the medicinal product in sterile setting
Information om bivirkningerne ved lavt blodsukker eller højt blodsukker findes i den indrammede del sidst i indlægssedlen.
For further information on the side effects of low blood sugar, see the box at the end of this leaflet.
Information om blødningsrisiko hos patienter med koagulationssygdomme herunder patienter i samtidig antikoagulationsbehandling.
Information on bleeding risk in patients with coagulation disorders including those on concurrent anti-coagulation therapy.
Information om bortskaffelse af ikke anvendt medicin
Information on the disposal of unwanted medication
INFORMATION OM BRAILLE-SKRIFT
INFORMATION IN BRAILLE
Information om dannelsen af et gel-depot og mulige reaktioner ved injektionsstedet
Information on gel depot formation and possible injections site reactions
Information om de anbefalede former for prævention for både kvinder og mænd
Information on the recommended forms of contraception both for women and men
Information om de anbefalede præventionsmetoder til både kvinder og mænd
Information on the recommended forms of contraception both for women and men
Information om de kardiovaskulære risici der er forbundet med anvendelsen af Tasigna
Information on the cardiac risks associated with the use of Tasigna
Information om de kliniske fund i udviklingsfasen (forhøjede leverenzymer og steatose) hos personer, der blev behandlet med Lojuxta
Information about clinical findings (i.e., hepatic enzyme increases and steatosis) in subjects treated with Lojuxta during the developmental phase;
Information om de omstændigheder, hvor HEMANGIOL ikke bør gives
Information on the conditions for which HEMANGIOL should not be given
Information om den identificerede risiko for synergistisk hepato- eller hæmatotoksicitet forbundet med kombinationsbehandling med andre DMARDs (Disease-Modifying Antirheumatic Drugs) (f.eks. methotrexat).
The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate)
Information om den identificerede risiko for synergistisk hepato- eller hæmatotoksicitet forbundet med kombinationsbehandling med andre DMARDs (Disease-Modifying Antirheumatic Drugs) (f.eks. methotrexat).
The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate).
Information om den korrekte indikation
Information on the correct indication
Information om den relative risiko for VTE eller ATE hos patienter med VTE eller ATE i anamnesen.
Information on relative risk of VTE or ATE in patients with a history of VTE or ATE
Information om det løbende LAL-mangel-register, herunder vigtigheden af at indskrive patienter, også dem, der ikke behandles med Kanuma, og modaliteterne til at deltage.
Information on the ongoing LAL Deficiency Registry, including the importance of enrolling patients, also those not treated with Kanuma, and the modalities for participation.
Information om eksistensen og vigtigheden af dette register, hvis formål er systematisk indsamling af information om sikkerheds- og virkningsmæssige resultater for patienter, der behandles med lomitapid.
Information about the existence and importance of the registry aiming to systematically collect information on the safety and effectiveness outcomes of patients treated with lomitapide.
Information om eksistensen og vigtigheden af Lomitapide Observational Worldwide Evaluation Registry, der systematisk indsamler oplysninger om sikkerheds- og virkningsmæssige udfald for patienter, der behandles med lomitapid
Information about the existence and importance of the Lomitapide Observational Worldwide Evaluation Registry aiming to systematically collect information on the safety and effectiveness outcomes of patients treated with lomitapide.
Information om erkendte og potentielle risici
Information on the identified and potential risks
Information om Fingolimod Pregnancy outcomes Intensive Monitoring Program and Pregnancy Exposure Registry
Information about the Fingolimod Pregnancy outcomes Intensive Monitoring Program and Pregnancy Exposure Registry
Information om fremgangsmåden ved behandling med Glybera
Information on the treatment procedure with Glybera
Information om følgende bivirkninger: o Infusionsreaktioner
Information about the following adverse reactions:
Information om herpetiske læsioner
Information of herpetic lesions
Information om hjælpestofferne
Information about excipients
Information om hvordan De vedligeholder Deres insulininhalator findes i brugsanvisningen, som findes i sidste del af denne indlægsseddel.
For instructions on how to look after your insulin inhaler see “Instructions for Use” at the end of the package leaflet.
Information om immunogenicitetsprøvetagning.
Immunogenicity sampling information.
Information om indberetning af bivirkninger, såfremt der er oprettet et særligt indberetningssystem.
If a specific notification system has been put in place, how to report adverse reactions.
Information om interaktioner med aliskiren
Information on aliskiren interactions
Information om interaktioner med CYP3A4-hæmmere og -induktorer, kumarin-antikoagulantia, statiner, P-gp-substrater, orale antikonceptionsmidler og galdesyresekvestranter
Information about interactions with CYP3A4 inhibitors and inducers, coumarin anticoagulants, statins, P-gp substrates, oral contraceptives, bile acid sequestrants;
Information om interaktioner med CYP3A4-hæmmere og -induktorer, kumarin-antikoagulantia, statiner, P-gp-substrater, orale antikonceptionsmidler, galdesyresekvestranter og grapefrugtjuice.
Information about interactions with CYP3A4 inhibitors and inducers, coumarin anticoagulants, statins, P-gp substrates, oral contraceptives, bile acid sequestrants and grapefruit juice;
Information om interaktioner med hydrochlorthiazid
Information on hydrochlorothiazide interactions
Information om interaktioner med Rasilamlo
Information on Rasilamlo interactions
Information om interaktionsstudier med andre lægemidler kendt fra de individuelle aktive substanser, er derfor beskrevet i dette afsnit.
Therefore, information on interactions with other medicinal products that are known for the individual active substances is provided in this section.
Information om justering af Tagrissodosis på grund af bivirkninger
TAGRISSO dose adjustment information for adverse reactions
Information om KIOVIG’s kildemateriale
Information on the source material of KIOVIG
Information om klargøring af en 0,25 ml dosis IXIARO til brug på børn under 3 år
Information on the preparation of a 0.25 ml dose of IXIARO for use in children below 3 years of age
Information om klargøring af en 0,25 ml-dosis IXIARO til brug på børn under 3 år
Information on the preparation of a 0.25 ml dose of IXIARO for use in children below 3 years of age